226 related articles for article (PubMed ID: 15741991)
1. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.
Tabolacci E; Pietrobono R; Moscato U; Oostra BA; Chiurazzi P; Neri G
Eur J Hum Genet; 2005 May; 13(5):641-8. PubMed ID: 15741991
[TBL] [Abstract][Full Text] [Related]
2. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome.
Coffee B; Zhang F; Ceman S; Warren ST; Reines D
Am J Hum Genet; 2002 Oct; 71(4):923-32. PubMed ID: 12232854
[TBL] [Abstract][Full Text] [Related]
3. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells.
Coffee B; Zhang F; Warren ST; Reines D
Nat Genet; 1999 May; 22(1):98-101. PubMed ID: 10319871
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene.
Chiurazzi P; Pomponi MG; Pietrobono R; Bakker CE; Neri G; Oostra BA
Hum Mol Genet; 1999 Nov; 8(12):2317-23. PubMed ID: 10545613
[TBL] [Abstract][Full Text] [Related]
5. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
6. Molecular dissection of the events leading to inactivation of the FMR1 gene.
Pietrobono R; Tabolacci E; Zalfa F; Zito I; Terracciano A; Moscato U; Bagni C; Oostra B; Chiurazzi P; Neri G
Hum Mol Genet; 2005 Jan; 14(2):267-77. PubMed ID: 15563507
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.
Pietrobono R; Pomponi MG; Tabolacci E; Oostra B; Chiurazzi P; Neri G
Nucleic Acids Res; 2002 Jul; 30(14):3278-85. PubMed ID: 12136110
[TBL] [Abstract][Full Text] [Related]
8. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.
Meng CF; Zhu XJ; Peng G; Dai DQ
World J Gastroenterol; 2007 Dec; 13(46):6166-71. PubMed ID: 18069755
[TBL] [Abstract][Full Text] [Related]
9. SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome.
Biacsi R; Kumari D; Usdin K
PLoS Genet; 2008 Mar; 4(3):e1000017. PubMed ID: 18369442
[TBL] [Abstract][Full Text] [Related]
10. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.
Nguyen CT; Weisenberger DJ; Velicescu M; Gonzales FA; Lin JC; Liang G; Jones PA
Cancer Res; 2002 Nov; 62(22):6456-61. PubMed ID: 12438235
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics, fragile X syndrome and transcriptional therapy.
Tabolacci E; Chiurazzi P
Am J Med Genet A; 2013 Nov; 161A(11):2797-808. PubMed ID: 24123753
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells.
Tabolacci E; Mancano G; Lanni S; Palumbo F; Goracci M; Ferrè F; Helmer-Citterich M; Neri G
Epigenetics Chromatin; 2016; 9():12. PubMed ID: 27014370
[TBL] [Abstract][Full Text] [Related]
13. Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines.
Lambrot R; Kimmins S
Int J Androl; 2011 Apr; 34(2):110-23. PubMed ID: 20497257
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.
Kawamoto K; Okino ST; Place RF; Urakami S; Hirata H; Kikuno N; Kawakami T; Tanaka Y; Pookot D; Chen Z; Majid S; Enokida H; Nakagawa M; Dahiya R
Clin Cancer Res; 2007 May; 13(9):2541-8. PubMed ID: 17473182
[TBL] [Abstract][Full Text] [Related]
15. Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation.
Mossman D; Scott RJ
PLoS One; 2011; 6(8):e23127. PubMed ID: 21829702
[TBL] [Abstract][Full Text] [Related]
16. The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome.
Kumari D; Usdin K
Hum Mol Genet; 2010 Dec; 19(23):4634-42. PubMed ID: 20843831
[TBL] [Abstract][Full Text] [Related]
17. The histone code regulating expression of the imprinted mouse Igf2r gene.
Yang Y; Li T; Vu TH; Ulaner GA; Hu JF; Hoffman AR
Endocrinology; 2003 Dec; 144(12):5658-70. PubMed ID: 12975326
[TBL] [Abstract][Full Text] [Related]
18. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation.
Tabolacci E; De Pascalis I; Accadia M; Terracciano A; Moscato U; Chiurazzi P; Neri G
Pharmacogenet Genomics; 2008 Aug; 18(8):738-41. PubMed ID: 18622267
[TBL] [Abstract][Full Text] [Related]
19. In vitro reactivation of the FMR1 gene involved in fragile X syndrome.
Chiurazzi P; Pomponi MG; Willemsen R; Oostra BA; Neri G
Hum Mol Genet; 1998 Jan; 7(1):109-13. PubMed ID: 9384610
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.
Yang Q; Tian Y; Ostler KR; Chlenski A; Guerrero LJ; Salwen HR; Godley LA; Cohn SL
BMC Cancer; 2010 Jun; 10():286. PubMed ID: 20546602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
